Hosted on MSN21d
Vera started at buy by Goldman Sachs, atacicept potential cited
Goldman Sachs has initiated coverage of Vera Therapeutics (NASDAQ:VERA) with a buy rating, citing the potential of its drug candidate atacicept and a recent pullback in the stock. The investment ...
Vera reaction to competitor IgAN update ‘overdone,’ says Goldman Sachs
Goldman Sachs notes that Vera Therapeutics (VERA) shares are down 18% and underperforming the biotech group today following earnings results ...
ETF Daily News19d
Vera Therapeutics (NASDAQ:VERA) Research Coverage Started at The Goldman Sachs Group
The Goldman Sachs Group started coverage on shares of Vera Therapeutics (NASDAQ:VERA – Free Report) in a research note issued to investors on Tuesday morning, Marketbeat reports. The firm issued ...
Business Insider22d
Vera Therapeutics initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Paul Choi initiated coverage of Vera Therapeutics (VERA) with a Buy rating and $58 price target Following the recent pullback, the firm sees Vera shares as at “an ...